A Combination Therapy In Patients With Social Anxiety Disorder
Phase 2
Completed
- Conditions
- Social Phobia
- Registration Number
- NCT00403962
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
The purpose of this study is to assess the efficacy, safety and tolerability of a combination of Vestipitant and Paroxetine in patients with Social Anxiety Disorder (SAD)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 204
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change in score on a Social Anxiety Disorder rating scale following 12 weeks of treatment.
- Secondary Outcome Measures
Name Time Method Change in score on a number of rating scales following 12 weeks of treatment assessing symptomatic, behavioural and functional parameters which together provide a more complete description of the disorder.
Trial Locations
- Locations (1)
GSK Investigational Site
🇿🇦Tygerberg, South Africa